Aims Despite advances in ST-segment elevation myocardial infarction (STEMI) treatment, a
sizeable minority of patients suffer poor outcomes even when treated with timely primary …

Background In patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI), potent oral inhibitors of the …

Background Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy
subjects and this action is further delayed in patients with acute myocardial infarction …

Background Oral P2Y12 inhibitors have a delayed onset of action in ST-segment elevation
myocardial infarction (STEMI) patients. We describe the first randomised controlled trial …

Background The action of oral P2Y12 inhibitors is delayed in patients with acute myocardial
infarction. Intravenous P2Y12 inhibition might lead to a more timely and potent antiplatelet …

Background Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy
subjects and this action is further delayed in patients with acute myocardial infarction …

Cangrelor was associated with marked reduced platelet reactivity as early as 5 minutes after
the start of infusion, which persisted during the entire duration of drug infusion, fulfilling the …

Background Cangrelor is a rapid onset and offset P2Y12-inhibitor with a recently approved
indication for patients treated with percutaneous coronary intervention (PCI) without …

Background Despite advances in ST-segment elevation myocardial infarction (STEMI)
treatment, a sizeable minority of patients suffer poor outcomes even when treated with timely …

This question sounds revolutionary but can be partially underlined by the fact that fast-acting
intravenous antiplatelet agents, such as glycoprotein IIb/IIIa blockers, were not in general …